Information Provided By:
Fly News Breaks for February 7, 2017
LJPC
Feb 7, 2017 | 07:31 EDT
SunTrust analyst Yatin Suneja expects upcoming Phase III data on La Jolla's LJPC-501 drug for catecholamine-resistant hypotension to be positive. Suneja says that the drug showed "proof-of-concept" in a Phase I study, and the analyst expects it to meet the primary endpoint in the Phase III study. Suneja thinks that the drug will be approved, and the analyst keeps a Buy rating on the stock.
News For LJPC From the Last 2 Days
There are no results for your query LJPC